LB2. Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial

BACKGROUND: Doravirine is a novel, non-nucleoside reverse-transcriptase inhibitor (NNRTI) that has demonstrated efficacy in two Phase 3 trials in treatment-naïve adults with HIV-1. METHODS: This open-label, active-controlled, noninferiority (NI) trial evaluated a once-daily single-tablet regimen of...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Open Forum Infect Dis
Päätekijät: Kumar, Princy, Johnson, Margaret, Molina, Jean-Michel, Rizzardini, Giuliano, Cahn, Pedro, Bickel, Markus, Mallolas, Josep, Zhou, Yan, Morais, Cristiana, Kumar, Sushma, Sklar, Peter, Hanna, George J, Hwang, Carey, Greaves, Wayne
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2018
Aiheet:
Abstracts
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6254879/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy229.2176
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia